Cullinan Therapeutics Secures FDA Clearance for CLN-978
CLN-978 marks a significant milestone as it becomes the first CD19 T cell engager to receive Investigational New Drug (IND) clearance from the U.S. FDA for treating autoimmune diseases. This groundbreaking achievement opens doors for innovative therapies aimed at patients battling moderate to severe systemic lupus erythematosus (SLE).
Details of the Clinical Trial
Cullinan Therapeutics has announced that the FDA has granted clearance for its IND application for CLN-978, allowing for the initiation of a global Phase 1 clinical trial. This study will assess the safety and efficacy of CLN-978 in individuals diagnosed with SLE who exhibit high disease activity. Specifically, patients must have a Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score of eight or higher, having previously shown inadequate response to at least two treatments, including one standard immunosuppressive or biologic agent.
Phases of the Study
The trial comprises two parts: Part A focuses on dose escalation to discover an optimal target dosage for future development, starting with a low dose of 10 micrograms. Part B will further explore various dosing schedules based on the insights gained from Part A.
Objectives of the Clinical Trial
The primary aim of this study is to gauge the safety of CLN-978 in treating patients with active moderate to severe SLE. Secondary objectives will encompass the examination of pharmacokinetics, B cell kinetics, immunogenicity, and overall clinical activity of the drug.
Dr. Jeffrey Jones, Chief Medical Officer of Cullinan Therapeutics, expressed enthusiasm regarding the continuation of this Phase 1 trial in the U.S. “There is a significant unmet need in treating systemic lupus erythematosus. Current therapies often do not provide sufficient control over disease activity or prevent damage to organs. Our candidate CLN-978 aims to address these issues through a unique approach,” he stated. This bispecific T cell engager is designed to target CD19 effectively, allowing for convenient subcutaneous delivery.
Background on CLN-978
CLN-978 is an innovative bispecific T cell engager engineered for high-affinity binding to CD19, which enables the targeting of even B cells with low CD19 expression. By triggering the destruction of CD19-expressing cells both in vitro and in vivo, this therapy offers a highly promising option for patients suffering from autoimmune diseases such as rheumatoid arthritis and SLE. Additionally, its small molecular size of 65 kDa ensures that it can be administered conveniently to patients without the need for complex protocols.
Understanding Systemic Lupus Erythematosus
Systemic lupus erythematosus is a chronic autoimmune condition characterized by the body's immune system mistakenly attacking its own tissues. Common symptoms include arthritis, skin rashes, extreme fatigue, and kidney complications. Alarmingly, about 40% of lupus patients develop lupus nephritis, which can have severe health implications, including increased mortality risk.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is committed to redefining standards of care for patients through innovative therapies aimed at addressing demanding medical needs. With a robust pipeline of clinical-stage assets, the company focuses on treatments that harness the immune system to eradicate diseased cells and inhibit the underlying causes of various diseases. Their expertise spans oncology and immunology, guiding the development of treatments that promise to be first or best in class.
To learn more about Cullinan Therapeutics, visit their website or follow them on platforms like LinkedIn and X.
Frequently Asked Questions
What is CLN-978?
CLN-978 is a CD19xCD3 bispecific T cell engager designed to treat autoimmune diseases such as systemic lupus erythematosus.
What did the FDA clearance for CLN-978 signify?
The FDA clearance allows Cullinan Therapeutics to proceed with its Phase 1 clinical trial, marking an important step in developing new autoimmune disease therapies.
What are the objectives of the Phase 1 clinical trial?
The trial aims to evaluate the safety of CLN-978 and to explore its pharmacokinetics, B cell kinetics, and clinical efficacy.
How is CLN-978 administered?
CLN-978 is administered subcutaneously, which provides ease of use for patients and allows for immediate therapeutic access.
Who is leading the clinical trial?
The clinical trial is spearheaded by Cullinan Therapeutics, with Dr. Jeffrey Jones being a key figure in its progression.
